FCF YoY
+24.65%
OCF YoY
+24.65%
Capex Change
+0.0
FCF Conversion Δ
—
Free cash flow bridge for Relmada Therapeutics (RLMD) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $14M
FCF bridge breakdown for Relmada Therapeutics (RLMD) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | -$56.8M | — |
| Operating Cash Flow | $14M | +100.0% |
| Capital Expenditure | $0.00 | +0.0% |
| Free Cash Outflow | -$42.8M | — |
- Prior Free Cash Flow-$56.8M
- Operating Cash Flow$14M
- Capital Expenditure$0.00
- Free Cash Outflow-$42.8M
Identity check: drivers reconcile to ΔNI within $1.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.